Total Funding
50
34
Total FundingVenture - Series Unknown raised
Growth Score 50 in past quarter
-6 pts
Heat Score 34 in past quarter
-9 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
42616
Philadelphia-based biotechnology company .
- Denise Barbut: Co-founder, President & CMOPast Role: Sarentis Therapeutics, Founder , Chairman & CEO
Michael Zasloff: Co-founder & CSO
About the Company
We are a clinical stage biopharmaceutical company engaged in the discovery and development of synthetic derivatives of newly discovered endogenous hormones that target misfolded proteins, including alpha-synuclein in Parkinson’s Disease, or PD, amyloid beta and tau in Alzheimer’s Disease, or AD, as well as targeting insulin resistance which is
central to the pathology of Type 2 Diabetes, or T2D, and AD. Our vision is to prevent the onset of these neurodegenerative and metabolic disorders, as well as to slow their progression.
Women Founded
